West Nile Virus Envelope Antibody is affinity chromatography purified via peptide column.
Immunogen
West Nile virus Envelope antibody was raised against a synthetic peptide corresponding to 15 amino acids near the center of the West Nile virus envelope protein. The immunogen is located within amino acids 500 - 550 of West Nile Virus Envelope.
WNV E
Reactivity: West Nile Virus (WNV)
IFA, EIA
Host: Mouse
Monoclonal
unconjugated
Application Notes
WNV Env antibody can be used for the detection of the West Nile virus Envelope protein in ELISA. It will detect 10 ng of free peptide at 1 μ,g/mL.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
West Nile Virus Envelope Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
West Nile Virus Envelope antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin.